Clinical Trials Directory

Trials / Unknown

UnknownNCT06154187

Study to Evaluate the Efficacy and Safety of PBK_L2201 in Postmenopausal Women With Osteoporosis

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel, Phase III Study to Evaluate the Efficacy and Safety of PBK_L2201 in Postmenopausal Women With Osteoporosis

Status
Unknown
Phase
Phase 3
Study type
Interventional
Enrollment
60 (estimated)
Sponsor
Pharmbio Korea Co., Ltd. · Industry
Sex
Female
Age
50 Years – 85 Years
Healthy volunteers
Not accepted

Summary

This clinical trial was multicenter, randomized, double-blind, placebo-controlled, parallel, phase III bridge study.

Conditions

Interventions

TypeNameDescription
DRUGPBK_L2201Abaloparatide-SC 80 μg was to be self-administered daily using a Pen Injector device.
DRUGPlaceboPlacebo was formulated similar to abaloparatide-SC.

Timeline

Start date
2024-02-01
Primary completion
2025-05-01
Completion
2025-11-01
First posted
2023-12-04
Last updated
2023-12-04

Locations

1 site across 1 country: South Korea

Source: ClinicalTrials.gov record NCT06154187. Inclusion in this directory is not an endorsement.

Study to Evaluate the Efficacy and Safety of PBK_L2201 in Postmenopausal Women With Osteoporosis (NCT06154187) · Clinical Trials Directory